sur BioVersys AG
BioVersys to Showcase BV100 Data at ESCMID Global 2025
BioVersys AG is set to present its Phase 2 data of BV100 at the 35th ESCMID Global 2025 conference. The event will be held from April 11-15, 2025, focusing on innovative treatments for multidrug-resistant bacteria. An oral presentation will highlight the efficacy and safety of BV100 in treating ventilator-associated bacterial pneumonia due to carbapenem-resistant Acinetobacter baumannii (CRAB).
The company will share extensive data, including poster presentations detailing both clinical and preclinical findings on BV100 and BV500. A symposium will address the global challenge of CRAB, exploring the potential of new antibiotics.
Dr. Glenn Dale, BioVersys's Chief Development Officer, expressed optimism about BV100 as a treatment for infections by CRAB, highlighting its strong survival benefits. The conference is an opportunity for BioVersys to present its advancements in combating antibiotic resistance.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de BioVersys AG